Relationship between human leukocyte antigen DRB1 and psoriasis in Iraqi patients

References

1. ↵
   1. Longo D,
   2. Kasper D,
   3. Jameson J,
   4. Fauci A,
   5. Hauser S,
   6. Loscalzo J

   (2012) Harrisons principle of internal medicine (McGraw-Hill, New York (NY)), 18th ed, p 398.
2. ↵
   1. Walker B,
   2. Colledge N,
   3. Ralston S,
   4. Penman I

   1. Ibbotson S,
   2. Dawe R

   (2014) in Davidson's principles and practice of Medicine, Skin Disease, eds Walker B, Colledge N, Ralston S, Penman I (Churchill Livingstone, Edinburgh (Scots)), p 1286.
3. ↵
   1. Giffiths C,
   2. Barker J,
   3. Bleiker T,
   4. Chalmers R,
   5. Creamer D

   1. Burden D,
   2. Kirby B

   (2016) in Rook's textbook of dermatology, Psoriasis and related disorders, eds Giffiths C, Barker J, Bleiker T, Chalmers R, Creamer D (Willy Blackwell, London (UK)), p 35.1.
4. ↵
   1. Krueger JG

   (2015) An autoimmune “attack” on melanocytes triggers soriasis and cellular hyperplasia. J Exp Med 212:2186.

   OpenUrlFREE Full Text
5. ↵
   1. Ogawa E,
   2. Sato Y,
   3. Minagawa A,
   4. Okuyama R

   (2018) Pathogenesis of psoriasis and development of treatment. J Dermatol 45:264–272.

   OpenUrl
6. ↵
   1. Chandran V,
   2. Bull SB,
   3. Pellett FJ,
   4. Ayearst R,
   5. Rahman P,
   6. Gladman DD

   (2013) Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Hum Immunol 74:1333–1338.

   OpenUrlCrossRefPubMed
7. ↵
   1. Okada Y,
   2. Han B,
   3. Tsoi LC,
   4. Stuart PE,
   5. Ellinghaus E,
   6. Tejasvi T,
   7. et al.

   (2014) Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet 95:162–172.

   OpenUrlCrossRefPubMed
8. ↵
   1. Harden JL,
   2. Krueger JG,
   3. Bowcock AM

   (2015) The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun 64:66–73.

   OpenUrlCrossRefPubMed
9. ↵
   1. Mahil SK,
   2. Capon F,
   3. Barker JN

   (2016) Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol 38:11–27.

   OpenUrl
10. ↵
    1. Atasoy M,
    2. Pirim I,
    3. Bayrak OF,
    4. Ozdemir S,
    5. Ikbal M,
    6. Erdem T,
    7. et al.

    (2006) Association of HLA class I and class II alleles with psoriasis vulgaris in Turkish population. Influence of type I and II psoriasis. Saudi Med J 27:373–376.

    OpenUrlPubMed
11. ↵
    1. Queiro R,
    2. Morante I,
    3. Cabezas I,
    4. Acasuso B

    (2016) HLA-B27 and psoriatic disease: a modern view of an old relationship. Rheumatology (Oxford) 55:221–229.

    OpenUrlCrossRefPubMed
12. ↵
    1. Barrea L,
    2. Nappi F,
    3. Di Somma C,
    4. Savanelli MC,
    5. Falco A,
    6. Balato A,
    7. et al.

    (2016) Environmental Risk Factors in Psoriasis: The Point of View of the Nutritionist. Int J Environ Res Public Health 13:E743.

    OpenUrl
13. ↵
    1. Enamandram M,
    2. Kimball AB

    (2013) Psoriasis epidemiology: the interplay of genes and the environment. J Invest Dermatol 133:287–289.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Yin X,
    2. Low HQ,
    3. Wang L,
    4. Li Y,
    5. Ellinghaus E,
    6. Han J,
    7. et al.

    (2015) Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. Nat Commun 6:6916.

    OpenUrlCrossRefPubMed
15. ↵
    1. Shawkatová I,
    2. Javor J,
    3. Párnická Z,
    4. Kozub P,
    5. Zilínková M,
    6. Frey P,
    7. et al.

    (2013) HLA-C, DRB1 and DQB1 alleles involved in genetic predisposition to psoriasis vulgaris in the Slovak population. Folia Microbiol (Praha) 58:319–324.

    OpenUrl
16. ↵
    1. Al-Mamari F,
    2. Al-Shirawi A,
    3. Banodkar D,
    4. Al-Hashmi S,
    5. Al-Yahyaae F,
    6. Varghese M,
    7. et al.

    (2009) HLA Antigens in Omani Psoriasis Vulgaris Patients. Oman Med J 24:27–29.

    OpenUrlPubMed
17. ↵
    1. Abdullah GA,
    2. Abbas MY,
    3. Hyam R,
    4. Mahdi BM,
    5. Zalzala HH,
    6. Abid LA,
    7. et al.

    (2015) The association between Human Leukocyte Antigen-DRB1 and vitiligo. European Journal of Medicine 10:190–194.

    OpenUrl
18. ↵
    1. Abdullah GA,
    2. Abbas MY,
    3. Mahdi BM,
    4. Raouf H,
    5. Zalzala HH,
    6. Abid LA,
    7. et al.

    (2016) Effect of HLA DRB1 on development of alopecia areata. International Journal of Research and Development in Pharmacy and Life Sciences 5:1910–1914.

    OpenUrl
19. ↵
    1. Tsai S,
    2. Santamaria P

    (2013) MHC Class II Polymorphisms, Autoreactive T-Cells, and Autoimmunity. Front Immunol 4:321.

    OpenUrlCrossRefPubMed
20. ↵
    1. Matzaraki V,
    2. Kumar V,
    3. Wijmenga C,
    4. Zhernakova A

    (2017) The MHC locus and genetic susceptibility to autoimmune and infectious diseases. Genome Biol 18:76.

    OpenUrlCrossRefPubMed
21. ↵
    1. Prinz JC

    (2018) Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis. Front Immunol 9:954.

    OpenUrlCrossRef
22. ↵
    1. Anzengruber F,
    2. Ghosh A,
    3. Maul JT,
    4. Drach M,
    5. Navarini AA

    (2018) Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis. Psoriasis (Auckl) 8:7–11.

    OpenUrl
23. ↵
    1. Costanzo A,
    2. Bianchi L,
    3. Flori ML,
    4. Malara G,
    5. Stingeni L,
    6. Bartezaghi M,
    7. et al.

    (Apr 28, 2018) Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol.
24. ↵
    1. Guarene M,
    2. Pasi A,
    3. Bolcato V,
    4. Cananzi R,
    5. Piccolo A,
    6. Sbarsi I,
    7. et al.

    (2018) The Presence of HLA-A Bw4-80I KIR Ligands Could Predict “Difficult-to-Treat” Psoriasis and Poor Response to Etanercept. Mol Diagn Ther 22:471–474.

    OpenUrl